sdgr-8k_20210511.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2021

 

Schrödinger, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

 

 

 

 

Delaware

 

 

 

95-4284541

(State or other jurisdiction of

incorporation or organization)

 

001-39206

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

 

 

120 West 45th Street, 17th Floor

New York, NY

 

 

 

10036

(Address of principal executive offices)

 

 

 

(Zip Code)

Registrant’s telephone number, including area code: (212) 295-5800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange on which registered

Common stock, par value $0.01 per share

  

SDGR

  

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 


 

 

Item 2.02

Results of Operations and Financial Condition.

On May 11, 2021, Schrödinger, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits:

 

Exhibit
Number

 

Description

99.1

  

Press release dated May 11, 2021

1


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

Schrödinger, Inc.

 

 

 

 

Date: May 11, 2021

 

 

 

By:

 

/s/ JOEL LEBOWITZ

 

 

 

 

 

 

Joel Lebowitz

Chief Financial Officer

 

2

sdgr-ex991_6.htm

 

 

Exhibit 99.1

 

Schrödinger Reports First Quarter 2021 Financial Results and Provides Company Update

 

First quarter total revenue of $32.1 million, up 23 percent year-over-year; Software revenue of $26.3 million, up 11 percent year-over-year

 

Expanded agreement with AstraZeneca; New agreement with NVIDIA

 

Development candidate selected for MALT1 inhibitor program; Internal pipeline progressing with plans to submit up to three investigational new drug applications to the FDA in 2022

 

Company maintains full-year 2021 financial outlook

 

New York, May 11, 2021 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results for the quarter ended March 31, 2021, and provided an update on the company.

 

“We had strong execution across multiple facets of our business during the quarter,” stated Ramy Farid, Ph.D., chief executive officer at Schrödinger. “We are continuing to advance our internal drug discovery pipeline and recently selected a development candidate for our MALT1 inhibitor program. Progress on our internal programs, coupled with our collaborators’ successes with molecules we’ve helped discover, are powerful examples that our platform and approach generates high-quality development candidates. We look forward to seeing the full impact of our technology as pharmaceutical, biotechnology and materials companies adopt our platform on a larger scale.”

 

Today the company announced an expanded collaboration with AstraZeneca to deploy Schrödinger’s computational platform to help accelerate drug discovery. The collaboration is an expansion of the agreement announced in September 2019, which was a pilot project across an initial small number of programs. Under the expanded agreement, AstraZeneca will fully deploy Schrödinger’s platform across all its structurally-enabled small molecule discovery programs.

 

First Quarter 2021 Financial Results

Revenue was $32.1 million for the first quarter of 2021, a 23 percent increase compared to the first quarter of 2020.

Software revenue was $26.3 million for the first quarter of 2021, an 11 percent increase compared to the first quarter of 2020.

Drug discovery revenue was $5.8 million for the first quarter of 2021, compared to $2.4 million in the first quarter of 2020.

Gross profit was $16.2 million in the first quarter of 2021, up three percent over the first quarter in 2020. Software gross margin was 78 percent in the first quarter of 2021, compared to 83 percent for the same period in the prior year.

Operating expenses for the first quarter of 2021 were $40.1 million, compared to $27.4 million in the first quarter of 2020.


 

Other income, which included losses on equity investments, changes in fair value of such investments and interest income, was $23.5 million in the first quarter of 2021 compared to a loss of $2.4 million for the first quarter of 2020. Other income for the first quarter of 2021 included a $24.8 million non-cash gain from the change in fair value of Schrödinger’s equity stake in Morphic Therapeutic. Additionally, in the first quarter of 2021, Schrödinger sold its equity stake in Relay Therapeutics, Inc. for cash proceeds of $15.7 million, which resulted in a non-cash loss of $1.8 million as a result of the fair value based on the share price of the Relay Therapeutics common stock at the sales date.

Net loss, after adjusting for non-controlling interests, was $0.0 million for the first quarter of 2021, compared to a net loss of $13.8 million in the first quarter of 2020.

 

Recent Business Highlights

Continued revenue growth and strategic execution

Reported 23 percent total revenue growth in the first quarter of 2021, driven by significant increase in drug discovery revenue in addition to continued uptake of Schrödinger’s core technologies including FEP+ and its enterprise solution, LiveDesign, as well as growth in new customers.

Ended the first quarter of 2021 with cash, cash equivalents, restricted cash and marketable securities of $649.0 million, compared to $643.2 million as of December 31, 2020.

 

Progressed internal pipeline

Selected a development candidate for the company’s MALT1 inhibitor program. Targeting MALT1 is emerging as a potential therapeutic strategy to treat certain relapsed or resistant B-cell lymphomas and chronic lymphocytic leukemia.

Continued to advance multiple programs toward IND-enabling studies; subject to completion of the preclinical data packages, the company expects to submit up to three IND applications in 2022, with the first submission to the FDA expected in the first half of next year.

Presented preclinical data on the company’s CDC7 inhibitor program at the American Association for Cancer Research (AACR) Annual Virtual Meeting. The data showed that Schrödinger’s picomolar CDC7 inhibitors were highly selective and inhibited tumor cell growth alone and in combination with several approved and investigational cancer treatments.

Advanced discovery efforts to allow addition of new programs to the company’s internal pipeline in 2021.

 

Continued investment in Schrödinger’s computational platform

Formed a strategic partnership with NVIDIA to further optimize Schrödinger’s software platform for the NVIDIA DGX SuperPODTM, an enterprise system that can be scaled to enable any organization to reach supercomputing speed and power. Optimizing Schrödinger’s platform for the NVIDIA GPU framework is designed to give customers access to an all-in-one supercomputing solution for in silico drug and materials discovery.

Further expanded the domain of applicability for Schrödinger’s software platform. Recently published research provided rationale for applying Schrödinger’s free energy calculation technology, FEP+, to ion channels using structures generated by cryo-electron microscopy (cryo-EM). The company’s scientists also published research describing a highly accurate method to predict the binding modes of small molecule inhibitors binding to protein targets with flexible binding sites, which have historically been challenging targets for structure-based drug design. Additionally, Schrödinger scientists co-authored a white paper describing how recent advances in protein production and cryo-EM can rapidly facilitate the structural enablement of drug targets.


 

 

Full-Year 2021 Financial Outlook

As of May 11, 2021, Schrödinger continues to expect total revenue to range from $124 million to $142 million, with software revenue expected to range from $102 million to $110 million and drug discovery revenue expected to range from $22 million to $32 million for the fiscal year ending December 31, 2021. Additional details are as follows:

Software revenue growth is expected to be higher in the second half of the year with the majority of second half growth in the fourth quarter of 2021.

Drug discovery revenue is expected to be highly variable quarter to quarter based on the timing of potential milestones related to collaborative agreements.

Schrödinger continues to aggressively fund R&D to advance its technology and drug discovery pipeline. The company expects operating expense growth to be higher than the 42% annual growth rate reported in 2020 and expects software gross margin to be lower than the 81% reported in 2020.

 

Webcast and Conference Call Information

Schrödinger will host a conference call to discuss its first quarter financial results on Tuesday, May 11, 2021, at 8:30 a.m. ET. The conference call can be accessed live by dialing (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and referring to conference ID 3297222. The webcast can also be accessed under “News & Events” in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. The archived webcast will be available on Schrödinger’s website following the event.

 

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

 

Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com and follow us on LinkedIn and Twitter.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding Schrödinger’s expectations about the speed and capacity of its computational platform, the company’s financial outlook for the fiscal year ending December 31, 2021, the company’s plans to continue to invest in research and its strategic plans to accelerate the growth of its software business and advance its collaborative and internal drug discovery programs, the company’s ability to improve and advance the science underlying its platform, including through the use of new technologies, the potential expansion of the domain of applicability of the company’s platform, the company’s ability to recognize potential benefits from its strategic partnerships, the clinical potential and favorable


 

properties of the company’s CDC7, MALT1, and Wee1 inhibitors, as well as the potential for its inhibitor programs to be used in combination with existing therapies, the timing of potential IND applications for its internal drug discovery programs, the ability to realize potential milestones, royalties or other payments under its collaborations, as well as the company’s expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond Schrödinger’s control, including the demand for its software solutions, the ability to further develop its computational platform, the reliance upon third-party providers of cloud-based infrastructure to host its software solutions, the reliance upon its third-party drug discovery collaborators, the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on its business and other risks detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the Securities and Exchange Commission on May 11, 2021, as well as future filings and reports by Schrödinger. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, the company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.

 

Contacts:

Jaren Irene Madden

Schrödinger, Inc.

jaren.madden@schrodinger.com

617-286-6264

 

Stephanie Simon (media)

Ten Bridge Communications

617-581-9333

 

 


 

 

Condensed Consolidated Statements of Operations (Unaudited)

 

(in thousands, except for share and per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

Software products and services

 

$

26,340

 

 

$

23,812

 

Drug discovery

 

 

5,787

 

 

 

2,362

 

Total revenues

 

 

32,127

 

 

 

26,174

 

Cost of revenues:

 

 

 

 

 

 

 

 

Software products and services

 

 

5,906

 

 

 

4,001

 

Drug discovery

 

 

10,057

 

 

 

6,548

 

Total cost of revenues

 

 

15,963

 

 

 

10,549

 

Gross profit

 

 

16,164

 

 

 

15,625

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

21,448

 

 

 

13,700

 

Sales and marketing

 

 

5,239

 

 

 

4,789

 

General and administrative

 

 

13,389

 

 

 

8,936

 

Total operating expenses

 

 

40,076

 

 

 

27,425

 

Loss from operations

 

 

(23,912

)

 

 

(11,800

)

Other (expense) income:

 

 

 

 

 

 

 

 

Loss on equity investments

 

 

(1,781

)

 

 

 

Change in fair value

 

 

24,824

 

 

 

(3,079

)

Interest income

 

 

420

 

 

 

699

 

Total other income (expense)

 

 

23,463

 

 

 

(2,380

)

Loss before income taxes

 

 

(449

)

 

 

(14,180

)

Income tax expense

 

 

74

 

 

 

91

 

Net loss

 

 

(523

)

 

 

(14,271

)

Net loss attributable to noncontrolling interest

 

 

(494

)

 

 

(445

)

Net loss attributable to Schrödinger common and

   limited common stockholders

 

$

(29

)

 

$

(13,826

)

Net loss per share attributable to Schrödinger

     common and limited common stockholders, basic

     and diluted:

 

$

 

 

$

(0.34

)

Weighted average shares used to compute net loss

     per share attributable to Schrödinger common and

     limited common stockholders, basic and diluted:

 

 

70,071,625

 

 

 

40,666,970

 



 

 

Condensed Consolidated Balance Sheets (Unaudited)

 

(in thousands, except for share and per share amounts)

 

 

 

 

 

 

 

 

 

 

Assets

 

March 31, 2021

 

 

December 31, 2020

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

133,122

 

 

$

202,296

 

Restricted cash

 

 

500

 

 

 

500

 

Marketable securities

 

 

515,372

 

 

 

440,395

 

Accounts receivable, net of allowance for doubtful accounts of $60 and $60

 

 

11,270

 

 

 

31,423

 

Unbilled and other receivables, net for allowance for unbilled receivables of $20 and $0

 

 

7,020

 

 

 

3,955

 

Prepaid expenses

 

 

7,954

 

 

 

4,409

 

Total current assets

 

 

675,238

 

 

 

682,978

 

Property and equipment, net

 

 

4,799

 

 

 

5,140

 

Equity investments

 

 

52,931

 

 

 

45,664

 

Right of use assets

 

 

8,865

 

 

 

10,129

 

Other assets

 

 

2,356

 

 

 

2,352

 

Total assets

 

$

744,189

 

 

$

746,263

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

7,220

 

 

$

8,398

 

Accrued payroll, taxes, and benefits

 

 

10,345

 

 

 

12,000

 

Deferred revenue

 

 

40,759

 

 

 

45,403

 

Lease liabilities

 

 

3,576

 

 

 

4,543

 

Other accrued liabilities

 

 

5,721

 

 

 

2,861

 

Total current liabilities

 

 

67,621

 

 

 

73,205

 

Deferred revenue, long-term

 

 

37,356

 

 

 

41,164

 

Lease liabilities, long-term

 

 

6,836

 

 

 

7,221

 

Other liabilities, long-term

 

 

600

 

 

 

654

 

Total liabilities

 

 

112,413

 

 

 

122,244

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock, $0.01 par value. Authorized 500,000,000 shares; 61,300,675 and 60,713,534 shares issued and

   outstanding at March 31, 2021 and December 31, 2020, respectively

 

 

613

 

 

 

607

 

Limited common stock, $0.01 par value. Authorized 100,000,000 shares; 9,164,193 shares issued and

   outstanding at March 31, 2021 and December 31, 2020, respectively

 

 

92

 

 

 

92

 

Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and

   outstanding at March 31, 2021 and December 31, 2020, respectively

 

 

 

 

 

 

Additional paid-in capital

 

 

760,574

 

 

 

752,558

 

Accumulated deficit

 

 

(129,588

)

 

 

(129,559

)

Accumulated other comprehensive income

 

 

77

 

 

 

317

 

Total stockholders’ equity of Schrödinger stockholders

 

 

631,768

 

 

 

624,015

 

Noncontrolling interest

 

 

8

 

 

 

4

 

Total stockholders’ equity

 

 

631,776

 

 

 

624,019

 

Total liabilities and stockholders’ equity

 

$

744,189

 

 

$

746,263

 



 

 

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(523

)

 

$

(14,271

)

Adjustments to reconcile net loss to net cash used in

 

 

 

 

 

 

 

 

operating activities:

 

 

 

 

 

 

 

 

Loss on equity investments

 

 

1,781

 

 

 

 

Noncash revenue from equity investments

 

 

(5

)

 

 

(46

)

Fair value adjustments

 

 

(24,824

)

 

 

3,079

 

Depreciation

 

 

887

 

 

 

877

 

Stock-based compensation

 

 

4,366

 

 

 

1,775

 

Noncash research and development expenses

 

 

498

 

 

 

435

 

Noncash investment accretion

 

 

1,955

 

 

 

83

 

Loss on disposal of property and equipment

 

 

19

 

 

 

 

Decrease (increase) in assets:

 

 

 

 

 

 

 

 

Accounts receivable, net

 

 

20,153

 

 

 

2,404

 

Unbilled and other receivables

 

 

(3,065

)

 

 

5,154

 

Reduction in the carrying amount of right of use assets

 

 

1,264

 

 

 

1,299

 

Prepaid expenses and other assets

 

 

(3,549

)

 

 

(1,106

)

Increase (decrease) in liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

(1,230

)

 

 

2,110

 

Accrued payroll, taxes, and benefits

 

 

(1,655

)

 

 

(2,289

)

Deferred revenue

 

 

(8,447

)

 

 

(3,378

)

Lease liabilities

 

 

(1,352

)

 

 

(1,266

)

Other accrued liabilities

 

 

2,806

 

 

 

(638

)

Net cash used in operating activities

 

 

(10,921

)

 

 

(5,778

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(513

)

 

 

(843

)

Purchases of equity investments

 

 

 

 

 

(2,869

)

Distribution from equity investment

 

 

40

 

 

 

 

Proceeds from sale of equity investments

 

 

15,735

 

 

 

 

Purchases of marketable securities

 

 

(143,671

)

 

 

(127,109

)

Proceeds from maturity of marketable securities

 

 

66,500

 

 

 

42,908

 

Net cash used in investing activities

 

 

(61,909

)

 

 

(87,913

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Issuances of common stock upon initial public offering, net

 

 

 

 

 

212,277

 

Issuances of common stock upon stock option exercises

 

 

3,656

 

 

 

177

 

Net cash provided by financing activities

 

 

3,656

 

 

 

212,454

 

Net (decrease) increase in cash and cash equivalents and restricted cash

 

 

(69,174

)

 

 

118,763

 

Cash and cash equivalents and restricted cash, beginning of period

 

 

202,796

 

 

 

26,486

 

Cash and cash equivalents and restricted cash, end of period

 

$

133,622

 

 

$

145,249

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow and noncash information

 

 

 

 

 

 

 

 

Cash paid for income taxes

 

$

119

 

 

$

64

 

Supplemental disclosure of non-cash investing and financing activities

 

 

 

 

 

 

 

 

Payment of deferred offering costs

 

 

 

 

 

786

 

Purchases of property and equipment

 

 

52

 

 

 

254

 

Acquisitions of right of use assets in exchange for lease obligations

 

 

 

 

 

1,778

 

Reclassification of deferred financing costs to additional paid in capital

 

 

 

 

 

1,858